Jian Cheng Zheng

US Patent:

7889674, Feb 15, 2011

Filed:

Aug 8, 2005

Appl. No.:

11/198168

Inventors:

Jong-hun Park - Suwon-si, KR
Jian liang Zheng - New York NY, US
Myung-jong Lee - New York NY, US

Assignee:

Samsung Electronics Co., Ltd. - Suwon-si
City University of New York - New York NY

International Classification:

H04L 12/28

US Classification:

370254

Abstract:

An address assigning method in a ZigBee network environment formed of a plurality of devices (or nodes), includes: linking the plurality of nodes in a cluster-tree structure; requesting desirable address blocks from a lowest level to a second highest level of the tree ancestor nodes desirable address blocks, respectively; and assigning the desired address blocks to descendents using a top-down procedure.

US Patent:

8148157, Apr 3, 2012

Filed:

Jan 7, 2009

Appl. No.:

12/349695

Inventors:

John W. Backus - Ontario NY, US
Jian Zheng - Raritan NJ, US
George Bashirians - Penfield NY, US

Assignee:

Ortho-Clinical Diagnostics, Inc. - Raritan NJ

International Classification:

G01N 31/00

US Classification:

436 15, 435 15

Abstract:

Disclosed herein are compositions and methods comprising two or more proteins in which at least one of the proteins has been altered to reduce their mutual recognition and binding. Such compositions are useful as reference, calibrators or controls in methods and assays for determining the amount of one or more of the proteins that may be present in a sample of interest or in confirming the presence of one or more of the proteins in the sample. More particularly, it relates to compositions and methods comprising altered placental growth factor-1 (PlGF-1) and soluble fms-like tyrosine kinase (sFlt-1) and methods for determining the amount or confirming the presence of sFlt-1 and/or PlGF-1 in a sample of interest.

US Patent:

20090176247, Jul 9, 2009

Filed:

Jan 7, 2009

Appl. No.:

12/350090

Inventors:

George Bashirians - Penfield NY, US
Deborah Byrne - Rochester NY, US
Sarah Groulx - Ontario NY, US
Sharon Jackson - Rochester NY, US
Heather Lane-Brown - Honeoye Falls NY, US
Banumathi Sankaran - Pittsford NY, US
Edward Scalice - Penfield NY, US
Karen Yang - Edison NJ, US
Jian Zheng - Raritan NJ, US

International Classification:

G01N 33/53
G01N 33/566

US Classification:

435 71, 436501

Abstract:

Methods for determining the presence or amount of a complex comprising a first and second molecular entity are provided, preferably an sFlt-1:PlGF complex. A determination of the presence or amount of the complex can be used in methods for predicting, detecting, monitoring a disease, or guiding therapy in respect to a disease such as vascular, vascular-related disease, cardiac, cardiac-related disease, cancer, cancer-related disease, preeclampsia, and preeclampsia-related disease. Determining sFlt-:angiogenic factor complex is particularly useful for predicting and detecting preeclampsia in early stages of gestation and in stages of the disease where clinical evaluation may be uninformative.

US Patent:

20120142035, Jun 7, 2012

Filed:

Feb 21, 2012

Appl. No.:

13/401263

Inventors:

John W. Backus - Ontario NY, US
Jian Zheng - Raritan NJ, US
George Bashirians - Penfield NY, US

International Classification:

G01N 33/53

US Classification:

435 792

Abstract:

Disclosed herein are compositions and methods comprising two or more proteins in which at least one of the proteins has been altered to reduce their mutual recognition and binding. Such compositions are useful as reference, calibrators or controls in methods and assays for determining the amount of one or more of the proteins that may be present in a sample of interest or in confirming the presence of one or more of the proteins in the sample. More particularly, it relates to compositions and methods comprising altered placental growth factor-1 (PlGF-1) and soluble fms-like tyrosine kinase (sFlt-1) and methods for determining the amount or confirming the presence of sFlt-1 and/or PlGF-1 in a sample of interest.

US Patent:

20140377778, Dec 25, 2014

Filed:

Sep 12, 2014

Appl. No.:

14/484869

Inventors:

- Raritan NJ, US
Deborah Byrne - Rochester NY, US
Sarah Groulx - Ontario NY, US
Sharon Jackson - Rochester NY, US
Heather Lane-Brown - Honeoye Falls NY, US
Banumathi Sankaran - Pittsford NY, US
Edward Scalice - Penfield NY, US
Karen Yang - Edison NJ, US
Jian Zheng - Raritan NJ, US

Assignee:

Ortho-Clinical Diagnostics, Inc. - Raritan NJ

International Classification:

G01N 33/68

US Classification:

435 721

Abstract:

Methods for determining the presence or amount of a complex comprising a first and second molecular entity are provided, preferably an sFlt-1:PlGF complex. A determination of the presence or amount of the complex can be used in methods for predicting, detecting, monitoring a disease, or guiding therapy in respect to a disease such as vascular, vascular-related disease, cardiac, cardiac-related disease, cancer, cancer-related disease, preeclampsia, and preeclampsia-related disease. Determining sFlt-1:angiogenic factor complex is particularly useful for predicting and detecting preeclampsia in early stages of gestation and in stages of the disease where clinical evaluation may be uninformative.